Download PDF
Klin Padiatr 2014; 226(06/07): 316-322
DOI: 10.1055/s-0034-1387748
Rapid Publication
© Georg Thieme Verlag KG Stuttgart · New York

Testicular Germ Cell Tumors in Adolescents – Results of the Protocol MAHO 98 and the Identification of Good Risk Patients

Hodentumoren bei Jugendlichen – Ergebnisse des Protokolls MAHO 98 und Evaluation der Prognosefaktoren
U. Göbel
1   Pediatric Oncology and Hematology, University Düsseldorf, Germany
,
G. Calaminus
2   Pediatric Hematology and Oncology, University Münster, Münster, Germany
,
R. Haas
3   Pediatric Hematology and Oncology, Ludwig-Maximilians-University ­Munich, Munich, Germany
,
C. Teske
2   Pediatric Hematology and Oncology, University Münster, Münster, Germany
,
S. Schönberger
4   Pediatric Hematology and Oncology, University of Bonn, Bonn, Germany
,
D. T. Schneider
5   Clinic for Pediatrics, Municipal Hospital, Dortmund, Germany
,
I. Leuschner
6   Kiel Paediatric Tumor Registry, Dept. of Paediatric Pathology, University of Kiel, Kiel, Germany
,
D. Harms
6   Kiel Paediatric Tumor Registry, Dept. of Paediatric Pathology, University of Kiel, Kiel, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
28 November 2014 (online)

Also available at
    Permissions and Reprints

Abstract

Background: In adolescents aged 10–15 years germ cell tumors of the testis (TGCT) are rare and information for a risk adapted therapy limited.

Aims of the study: The protocol MAHO 98 for patients (pts) with TGCTs is stratified according to age, stage and histology. Pts ≥10 years received after tumororchiectomy 2 courses (crs) PVB and restaging. Residual tumor was resected and therapy continued in regard to inital stage and response.

Chemotherapy: PVB: cisplatin (20 mg/m²/day 1–5), vinblastine (3 mg/m²/day 1+2), and bleomycin (15 U/m²/day 1–3). For consolidation 1 crs PVB has been given to stage II patients with CR. In case of PR, 2 crs PEB (vinblastine substituted by etoposide 100 mg/m²/day 1–3) or relapse 3 crs PEI (bleomycin substituted by ifosfamide 1 500 mg/m²/day 1–5) were given.

Results: Between Jan 1998 and Dec 2005, 34 pts (≥10 year) were registered, 31 fulfilled the inclusion criteria. Median age: 15;6 years; months (range 13;5–20;2 ). Lugano staging: IA n=14, IB n=2, IC n=3, IIA n=4, IIB n=6, IIC n=1, IIIC n=1. The stage IIIC pt received preoperative chemotherapy, all other pts had tumororchiectomy first. Residual tumor after 2 crs PVB was detected in 4 pts and was resected. Late relapses occurred in 2 pts and were cured by additional therapy. All patients are surviving.

Conclusion: Young patients with TGCT stage I and II have an excellent prognosis and further reduction of therapy has to be considered.

Zusammenfassung

Hintergrund: Testikuläre Keimzelltumoren (TGCT) bei 10–15 jährigen Jungen sind selten und Daten zur Risiko-adaptierten Therapie spärlich.

Ziele der Studie: In dem GPOH-Protokoll MAHO 98 erhielten die Patienten (≥10 years) nach Tumororchiektomie einheitlich 2 Kurse PVB. Residuale Metastasen wurden reseziert und die Therapie entsprechend dem Ansprechen fortge­setzt.

Chemotherapie: PVB: Cisplatin (20 mg/m²/Tag 1–5), Vinblastin (3 mg/m²/Tag 1+2) und Bleomycin (15 U/m²/Tag 1–3). Zur Konsolidierung wurden bei Stadium II und CR 1 Kurs PVB, bei PR 2 Kurse PEB (Etoposid 100 mg/m²/Tag 1–3 statt Vinblastin), bzw. bei Rückfall 3 Kurse PEI (Ifosfamid 1 500 mg/m²/Tag 1–5 statt Bleomycin) verabreicht.

Ergebnisse: Es wurden 34 Patienten ≥10 Jahre registrieret; 31 Patienten erfüllten die einschlusskriterien. Alter: Median 15;6 Jahre (Schwankungsbreite 13;5–20;2). Lugano Sta­dien: IA n=14, IB n=2, IC n=3, IIA n=4, IIB n=6, IIC n=1, IIIC n=1. Der Patient mit Stadium IIIC erhielt präopertative Chemotherapie, alle anderen Patienten initial eine Tumororchiektomie. Residualer Tumor nach 2 Kursen PVB wurde bei 4 Patienten gefunden und reseziert. Die Ansprechrate auf das Protokoll betrug 31/31, jedoch wurden 2 späte Rückfälle registriert und erfolgreich nachbehandelt. Alle Patienten über­leben tumorfrei.

Schlussfolgerung: Junge Patienten mit malignem TGCT des Stadiums I oder II haben mit dem Protokoll MAHO 98 eine excellente Prognose. Über weitere Reduktionen der Therapie ist nachzudenken.

Key words

testicular germ cell tumor - stratified therapy in adolescents - preoperative chemotherapy - response rate

Schlüsselwörter

testikulare Keimzelltumoren - präoperative Chemotherapie - Ansprechrate - Risiko-adaptierte Therapie bei Jugendlichen

Supplementary Material

 

  • References

  • 1 Albers P, Albrecht W, Algaba F et al. EAU guidelines on testicular cancer: 2011 update. Eur Urol 2011; 60: 304-319
    CrossrefPubMedGoogle Scholar
  • 2 Bernig T, Jahn F, Witkowsky S et al. Treatment of adolescents and young adults (AYA) with cancer in a multidisciplinary setting: On the way to a highly specialized AYA Unit. Klin Padiatr 2013; 225: 335-338
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Bremmer F, Behnes CL, Schweyer S. Non-seminomatous germ cell tumours. Pathologe 2014; 35: 238-244
    CrossrefPubMedGoogle Scholar
  • 4 Bussey KJ, Lawce HJ, Olson SB et al. Chromosome abnormalities of eighty-one pediatric germ cell tumors: sex-, age-, site-, and histopathology- related differences – a Children’s Cancer Group study. Genes Chromosomes Cancer 1999; 25: 134-146
    CrossrefPubMedGoogle Scholar
  • 5 Calaminus G, Bamberg M, Harms D et al. AFP/beta-HCG secreting CNS germ cell tumors: long-term outcome with respect to initial symptoms and primary tumor resection. Results of the cooperative trial MAKEI 89 Neuropediatrics 2005; 36: 71-77
    PubMedGoogle Scholar
  • 6 Cavalli F, Monfardini S, Pizzocaro G. Report on the International Workshop on Staging and Treatment of Testicular Cancer. Eur J Cancer 1980; 16: 1367-1372
    CrossrefPubMedGoogle Scholar
  • 7 Dehner LP. Gonadal and extragonadal germ cell neoplasia of childhood. Hum Pathol 1983; 14: 493-511
    CrossrefPubMedGoogle Scholar
  • 8 Dieckmann KP, Wilken S, Loy V et al. Treatment of testicular intraepithelial neoplasia (intratubular germ cell neoplasia unspecified) with local radiotherapy or with platinum-based chemotherapy: a survey of the German Testicular Cancer Study Group. Ann Oncol 2013; 24: 1332-1337
    CrossrefPubMedGoogle Scholar
  • 9 Einhorn LH, Donohue JP. Chemotherapy for disseminated testicular cancer. Urol Clin North Am 1977; 4: 407-426
    PubMedGoogle Scholar
  • 10 Ferreira CG, de Melo AC, Nogueira-Rodrigues A. The adolescent and young adult with cancer: state of the art-epithelial cancer. Curr Oncol Rep 2013; 15: 287-295
    CrossrefPubMedGoogle Scholar
  • 11 Frazier AL, Rumcheva P, Olson T et al. Application of the adult international germ cell classification system to pediatric malignant non-seminomatous germ cell tumors: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2008; 50: 746-751
    CrossrefPubMedGoogle Scholar
  • 12 Göbel U, Haas R, Calaminus G et al. Testicular germ cell tumors in boys <10 years: results of the protocol MAHO 98 in respect to surgery and watch & wait strategy. Klin Padiatr 2013; 225: 296-302
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Göbel U, Schneider DT, Calaminus G et al. Germ-cell tumors in childhood and adolescence. GPOH MAKEI and the MAHO study groups. Ann Oncol 2000; 11: 263-271
    CrossrefPubMedGoogle Scholar
  • 14 Haas RJ, Bamberg M, Calaminus G et al. Cooperative, prospektive, nicht randomisierte Therapiestudie Maligne Hodentumoren im Kindesalter MAHO 98. München: 1998
    Google Scholar
  • 15 Haas RJ, Schmidt P, Göbel U et al. Treatment of malignant testicular tumors in childhood: results of the German National Study 1982–1992. Med Pediatr Oncol 1994; 23: 400-405
    CrossrefPubMedGoogle Scholar
  • 16 Harms D, Jänig U. Germ cell tumours of childhood. Report of 170 cases including 59 pure and partial yolk-sac tumours. Virchows Arch A Pathol Anat Histopathol 1986; 409: 223-239
    CrossrefPubMedGoogle Scholar
  • 17 Heidenreich A, Knüchel-Clarke R, Pfister D. Importance of pathology for therapy planning of testicular germ cell tumors. Pathologe 2014; 35: 266-273 DOI: 10.1007/s00292-014-1903-5.
    CrossrefPubMedGoogle Scholar
  • 18 Hofmann M, Schlegel PG, Hippert F et al. Testicular sex cord stromal tumors: analysis of patients from the MAKEI study. Pediatr Blood Cancer 2013; 60: 1651-1655
    CrossrefPubMedGoogle Scholar
  • 19 Li MC, Whitmore WFJR, Golbey R et al. Effects of combined drug therapy on metastatic cancer of the testis. JAMA 1960; 174: 1291-1299
    CrossrefPubMedGoogle Scholar
  • 20 Mostofi FK, Sesterhenn IA. Tumours of the testis and paratesticular tissue (chapter 4). In Eble JN, Sauter G, Epstein JL, Sesterhenn IA. (eds.). Pathology and genetics. Tumours of the urinary system and male genital disorders. WHO classification of tumours. IARC Press; 2004
    Google Scholar
  • 21 Mostofi FK, Sobin LH. Histopathological typing of testis tumors. Geneva: WHO; 1977
    Google Scholar
  • 22 Oosterhuis JW, Looijenga IH. Testicular germ-cell tumours in a broader perspective. Nat Rev Cancer 2005; 5: 210-222
    CrossrefPubMedGoogle Scholar
  • 23 Poynter JN, Amatruda JF, Ross JA. Trends in incidence and survival of pediatric and adolescent patients with germ cell tumors in the United States, 1975 to 2006. Cancer 2010; 116: 4882-4891
    CrossrefPubMedGoogle Scholar
  • 24 Schmoll HJ, Jordan K, Huddart R et al. Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; (Suppl. 05) v147-v154
    PubMedGoogle Scholar
  • 25 Schneider DT, Calaminus G, Göbel U. Diagnostic value of alpha 1-fetoprotein and beta-human chorionic gonadotropin in infancy and childhood. Pediatr Hematol Oncol 2001; 18: 11-26
    CrossrefPubMedGoogle Scholar
  • 26 Schneider DT, Calaminus G, Koch S et al. Epidemiological analysis of 1442 children and adolescents registered in the German germ cell tumor protocols. Pediatr Blood & Cancer 2004; 42: 169-175
    PubMedGoogle Scholar
  • 27 Schrader M, Weissbach L, Hartmann M et al. Burden or Relief: Do second-opinion centers influence the quality of care delivered to patients with testicular germ cell cancer?. Eur Urol 2010; 57: 867-872
    CrossrefPubMedGoogle Scholar
  • 28 Sonneveld DJ, Schraffordt Koops H et al. Bilateral testicular germ cell tumours in patients with initial stage I disease: prevalence and prognosis – a single centre’s 30 years’ experience. Eur J Cancer 1998; 34: 1363-1367
    CrossrefPubMedGoogle Scholar
  • 29 Sonneveld DJ, Sleijfer DT, Koops HS et al. Mature teratoma identified after postchemotherapy surgery in patients with disseminated nonseminomatous testicular germ cell tumors: a plea for an aggressive surgical approach. Cancer 1998; 82: 1343-1351
    CrossrefPubMedGoogle Scholar
  • 30 Vasdev N, Moon A, Thorpe AC. Classification, epidemiology and therapies for testicular germ cell tumours. Int J Dev Biol 2013; 57: 133-139
    CrossrefPubMedGoogle Scholar
  • 31 Verdorfer I. Genetics of testicular germ cell tumors. Pathologe 2014; 35: 218-223
    PubMedGoogle Scholar
  • 32 Weißbach L, Hildebrand G. Register- und Verbundstudie für Hodentumoren – Bonn. München: Zuckschwerdt Verlag München; 1982
    Google Scholar
  • 33 Zahn S, Sievers S, Alemazkour K et al. Imbalances of chromosome 1p in pediatric and adult germ cell tumors are caused by true allelic loss: a combined comparative genomic hybridization and microsatellite analysis. Genes Chromosomes Cancer 2006; 45: 995-1006
    CrossrefPubMedGoogle Scholar